Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 318 Shares

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 318 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $76.99, for a total transaction of $24,482.82. Following the transaction, the president now directly owns 1,443,002 shares of the company’s stock, valued at approximately $111,096,723.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Stephen Hoge also recently made the following trade(s):

• On Thursday, August 29th, Stephen Hoge sold 300 shares of Moderna stock. The stock was sold at an average price of $78.03, for a total transaction of $23,409.00.
• On Monday, August 12th, Stephen Hoge sold 254 shares of Moderna stock. The shares were sold at an average price of $84.10, for a total value of $21,361.40.
• On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00.
• On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00.

Moderna Trading Down 0.6 %

Shares of MRNA opened at $72.49 on Thursday. The business’s 50-day moving average price is $102.13 and its 200 day moving average price is $112.97. The stock has a market capitalization of $27.78 billion, a P/E ratio of -4.63 and a beta of 1.67. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s revenue was down 29.9% on a year-over-year basis. During the same quarter last year, the business posted ($3.62) EPS. Analysts expect that Moderna, Inc. will post -9.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of recent analyst reports. Royal Bank of Canada cut shares of Moderna from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $125.00 to $90.00 in a research note on Monday, August 5th. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $96.00 to $88.00 and set a “neutral” rating for the company in a research note on Thursday, August 15th. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Barclays decreased their price target on Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research note on Friday, August 2nd. Ten equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $123.79.

Hedge Funds Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the business. Cedar Wealth Management LLC grew its stake in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Commerzbank Aktiengesellschaft FI grew its stake in Moderna by 1.7% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after acquiring an additional 93 shares in the last quarter. CVA Family Office LLC lifted its holdings in shares of Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after buying an additional 96 shares during the last quarter. Claro Advisors LLC lifted its holdings in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after buying an additional 108 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after buying an additional 116 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.